Skip to main content
Log in

Overview

Promoting rational therapy within the discipline of cardiology, the American Journal of Cardiovascular Drugs covers all aspects of the treatment of cardiovascular disorders, particularly the place in therapy of newer and established agents.

Via a program of reviews and original clinical research articles, the journal addresses major issues relating to treatment of these disorders, including the pharmacology, efficacy and adverse effects of the major classes of drugs; information on newly developed drugs and drug classes; the therapeutic implications of latest research into the aetiology of cardiovascular disorders; and the practical management of specific clinical situations.

As a hybrid journal, the American Journal of Cardiovascular Drugs does not charge authors to publish using the traditional subscription-based publishing route, but does offer the option to publish accepted articles open access if authors so wish or if their funders require. This is achieved via the Springer Open Choice™ initiative. More information about this optional route to open access and the associated article processing charge can be found by clicking on the ‘How to publish with us, including Open Access’ link below.

The American Journal of Cardiovascular Drugs offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand the scientific content and overall implications of the article. The journal also provides the option to include various types of digital features including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations. All additional features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager®, supported by a database of international experts. This database is shared with other Adis journals.

Editor
  • Amitabh Prakash
Impact factor
3.0 (2022)
5 year impact factor
2.9 (2022)
Submission to first decision (median)
9 days
Downloads
232,455 (2023)

Societies and partnerships

  • International Academy of Cardiovascular Sciences
    International Academy of Cardiovascular Sciences

Latest articles

Journal updates

  • Digital Features

    The American Journal of Cardiovascular Drugs is able to host a range of digital features, with a number of options available to authors.

Journal information

Electronic ISSN
1179-187X
Print ISSN
1175-3277
Abstracted and indexed in
  1. BFI List
  2. Baidu
  3. CLOCKSS
  4. CNKI
  5. CNPIEC
  6. Chemical Abstracts Service (CAS)
  7. Current Contents/Clinical Medicine
  8. Dimensions
  9. EBSCO
  10. EMBASE
  11. Google Scholar
  12. Japanese Science and Technology Agency (JST)
  13. Medline
  14. Naver
  15. OCLC WorldCat Discovery Service
  16. Pathway Studio
  17. Portico
  18. ProQuest
  19. Reaxys
  20. SCImago
  21. SCOPUS
  22. Science Citation Index Expanded (SCIE)
  23. Semantic Scholar
  24. TD Net Discovery Service
  25. UGC-CARE List (India)
  26. Wanfang
Copyright information

Rights and permissions

Springer policies

© Springer Nature Switzerland AG

Navigation